SOURCE: Novo Nordisk A/S

March 01, 2010 08:41 ET

Novo Nordisk A/S: Transaction in Own Shares

BAGSVAERD, DENMARK--(Marketwire - March 1, 2010) -


Novo Nordisk A/S - Share repurchase programme

On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.


Since the announcement as of 22 February 2010, the following transactions have been made under the programme:

                   Number of    Average     Transaction value,
                    shares   purchase price        DKK

 Accumulated, last 1,305,000                       496,879,259
 announcement

 22 February 2010     85,000       396.5120         33,703,520

 23 February 2010    155,000       389.5312         60,377,336

 24 February 2010     91,000       391.8990         35,662,809

 25 February 2010     90,000       387.4210         34,867,890

 26 February 2010     85,000       386.0500         32,814,250

 Accumulated under 1,811,000                       694,305,064
 the programme

With the transactions stated above, Novo Nordisk owns a total of 32,082,298 treasury shares, corresponding to 5.2% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.


Further information:

Media:                             Investors:

Elin K Hansen                       Klaus Bülow Davidsen
Tel: (+45) 4442 3450                Tel: (+45) 4442 3176
ekh@novonordisk.com                 klda@novonordisk.com

                                    Kasper Roseeuw Poulsen
                                    Tel: (+45) 4442 4471
                                    krop@novonordisk.com

In North America:                   In North America:
Sean Clements                       Hans Rommer
Tel: (+1) 609 514 8316              Tel: (+1) 609 919 7937
secl@novonordisk.com                hrmm@novonordisk.com

Company Announcement no 12 / 2010


[HUG#1389574]

Company Announcement no 12 2010: http://hugin.info/2013/R/1389574/347705.pdf

Contact Information